The WuXi AppTec, Celgene, Taikang and Tigermed-backed cancer drug developer went public in Hong Kong at the top of its range.
China-based oncology therapy developer Antengene floated on Friday in an initial public offering sized at about HK$2.79bn ($360m) that achieved exits for corporates WuXi AppTec, Celgene, Taikang and Tigermed, DealStreetAsia reported. The company issued just over 154 million shares on the main board of the Hong Kong Stock Exchange priced at the top of the…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.